免疫不全患者におけるCOVID–19 疾病負担

Naho Kuroishi, Shinichi Kanazu, Takahiro Takazono, Akinao Okamoto, Akihiro Tomita, Shigeyoshi Yamanaga, Takashi Kenmochi, Hiroto Egawa, Kento Inoue, Hirokazu Kanegane, Toshibumi Taniguchi, Kenji Oku, Kan Kikuchi, Hiroshi Yotsuyanagi

研究成果: ジャーナルへの寄稿学術論文査読

抄録

Immuno compromised patients with congenital or acquired immune function-related abnormalities and those with depressed immune function due to the effects of medication(s) for treating another disease(s) are at greater risk of severe COVID-19 or death after contracting COVID-19 than the general population. Therefore, measures for preventing COVID-19 are extremely important in immuno compromised patients. However, the antibody response after vaccination is lower in immuno compromised patients than that in the general population due to the nature of the disease, i.e., immune deficiency. In this paper, we discuss the immune state and the effectiveness of COVID-19 vaccines in patients with hematological malignancies, solid organ transplantation, primary immunodeficiency disease, human immunodeficiency virus, rheumatic disease, and renal disease. We also consider the importance of new infection-preventing measures in addition to vaccines.

寄稿の翻訳タイトルCOVID-19 Disease Burden in Immunocompromised Patients
本文言語日本語
ページ(範囲)881-897
ページ数17
ジャーナルTherapeutic Research
44
12
出版ステータス出版済み - 2023

All Science Journal Classification (ASJC) codes

  • 医学一般

フィンガープリント

「免疫不全患者におけるCOVID–19 疾病負担」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル